Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China.

Zhengyang Fei,Mingjun Rui,Yingcheng Wang,Aixia Ma

Expert review of pharmacoeconomics & outcomes research（2023）

引用 1|浏览5

暂无评分

摘要

The findings suggest that anlotinib could be the most cost-effective option versus pembrolizumab and nivolumab in the third-line treatment of recurrent SCLC from the Chinese healthcare system perspective.

查看译文

关键词

Anlotinib,China,cost-effective,long-term survival,nivolumab,pembrolizumab,small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要